This article is more than 5 years old. Information may no longer be current.
Top 5 spondyloarthritis research articles highlight NSAIDs, biologics, biosimilars
Click Here to Manage Email Alerts
Highly read articles on Healio/Rheumatology about recently published research regarding spondyloarthropathies have focused on the use of NSAIDs, biologic and biosimilar medications. Prognostic factors, such as risk factors for fracture and bone marrow edema, were topics of interest, in addition to pediatric issues related to spondyloarthropathies.
BMD improved with etanercept in patients with AS, but fracture risk remained
Patients with ankylosing spondylitis (AS) had improvements in bone mineral density (BMD) after treatment with etanercept, but the risk for fracture remained high, according to researchers at the Jan van Breemen Research Institute/Reade in Amsterdam. Read more.
Researchers identify prognostic factors for spondyloarthritis outcomes
Low education level, older age, high disease activity at onset, positive smoking status and female sex were cited as prognostic factors of poor functional outcomes in patients with early inflammatory back pain, according to researchers in France. Read more.
Sacroiliitis seen on MRI common among children with SpA
The presence of sacroiliitis as evidenced on MRI was common in a study of children with juvenile spondyloarthritis (SpA), and HLA-B27-positivity and elevated C-reactive protein were most likely to predict the presence of sacroiliitis, according to recently published research. Read more.
Etoricoxib may relieve some symptoms of axial ankylosing spondylitis
Etoricoxib may be a potential therapy for patients with axial ankylosing spondylitis who do not respond well to traditional NSAIDs and may provide an alternative to biologics for some patients, according to a recently published report. Read more.
Lower rate of uveitis seen among patients with axSpA treated with certolizumab pegol
Patients with axial spondyloarthritis (axSpA) had a lower rate of uveitis following treatment with certolizumab pegol compared to patients who received placebo, according to recently published research. Read more.